{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T19:07:24Z","timestamp":1781118444579,"version":"3.54.1"},"reference-count":28,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:00:00Z","timestamp":1559088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Tyrosine kinase inhibitors (TKIs) can significantly prolong overall survival for patients with advanced non\u2010small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (<jats:italic>EGFR<\/jats:italic>)\u2010mutation or anaplastic lymphoma kinase (<jats:italic>ALK<\/jats:italic>)\u2010rearrangement. However, the real\u2010world evaluation status of ALK\/EGFR in China remains unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a prospective study including 1134 patients with cytologically or histologically confirmed advanced NSCLC (stage IIIb\u2013IV) at 12 Chinese hospitals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The most common evaluation methods were amplification\u2010refractory mutation system for <jats:italic>EGFR<\/jats:italic> status and immunohistochemistry targeting D5F3 for <jats:italic>ALK<\/jats:italic> status. Among patients with non\u2010squamous, the <jats:italic>EGFR<\/jats:italic> mutation rate was 44.1% and the <jats:italic>ALK<\/jats:italic> rearrangement rate was 10.0%. Among patients with squamous cell carcinoma, the <jats:italic>EGFR<\/jats:italic> mutation rate was 8.3% and the <jats:italic>ALK<\/jats:italic> rearrangement rate was 3.7%. Among all patients, gender (HR = 1.7, 95%CI = 1.2\u20132.4, <jats:italic>P<\/jats:italic> = 0.006), smoking history (HR = 1.8, 95%CI = 1.3\u20132.7, <jats:italic>P<\/jats:italic> = 0.001), histology (HR = 5.0, 95%CI = 2.4\u201310.1, <jats:italic>P<\/jats:italic> &lt; 0.001), and brain metastases (HR = 1.5, 95%CI = 1.1\u20132.2, <jats:italic>P<\/jats:italic> = 0.017) were independent predictors of <jats:italic>EGFR<\/jats:italic> mutation, while age (HR = 2.6, 95%CI = 1.7\u20134.1, <jats:italic>P<\/jats:italic> &lt; 0.001) was an independent predictor of <jats:italic>ALK<\/jats:italic> rearrangement. The median time from tumor diagnosis to <jats:italic>EGFR<\/jats:italic> or <jats:italic>ALK<\/jats:italic> status confirmation was 7 and 5 days, respectively. Targeted therapy rate was 73.8% in <jats:italic>EGFR<\/jats:italic>\u2010positive patients and 51.4% in <jats:italic>ALK<\/jats:italic>\u2010positive patients. There was a negative correlation between the first\u2010line targeted therapy rate and the <jats:italic>EGFR<\/jats:italic> mutation detection period (r = \u22120.152, <jats:italic>P<\/jats:italic> = 0.02), while no significant correlation among patients with <jats:italic>ALK<\/jats:italic> rearrangement (r = \u22120.179, <jats:italic>P<\/jats:italic> = 0.076).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Squamous NSCLC patients should also be routinely tested to determine their <jats:italic>EGFR<\/jats:italic>\/<jats:italic>ALK<\/jats:italic> statuses. The first\u2010line targeted therapy rate remains low in Chinese patients with NSCLC.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1759-7714.13090","type":"journal-article","created":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T04:10:07Z","timestamp":1559189407000},"page":"1521-1532","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Real\u2010world data on EGFR\/ALK gene status and first\u2010line targeted therapy rate in newly diagnosed advanced non\u2010small cell lung cancer patients in Northern China: A prospective observational study"],"prefix":"10.1111","volume":"10","author":[{"given":"Hongge","family":"Liang","sequence":"first","affiliation":[{"name":"Respiratory Medicine Peking Union Medical College Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Song","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Shanxi Provincial Cancer Hospital  Taiyuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Beijing Chaoyang Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shucai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical Oncology Beijing Chest Hospital, Capital Medical Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Li","sequence":"additional","affiliation":[{"name":"Medical Oncology Military General Hospital of Beijing  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Fang","sequence":"additional","affiliation":[{"name":"Medical Oncology Beijing Cancer Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junling","family":"Li","sequence":"additional","affiliation":[{"name":"Medical Oncology Chinese Academy of Medical Sciences Cancer Institute and Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liang","sequence":"additional","affiliation":[{"name":"Medical Oncology Peking University Third Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligong","family":"Nie","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Peking University First Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kewei","family":"Ma","sequence":"additional","affiliation":[{"name":"Medical Oncology Jilin University First Hospital  Changchun China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical Oncology Qindao University Medical College Affiliated Yantai Yuhuangding Hospital  Yantai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical Oncology Baotou Cancer Hospital  Baotou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjun","family":"Xu","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Shanxi Provincial Cancer Hospital  Taiyuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"Wei","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Beijing Chaoyang Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghui","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical Oncology Beijing Chest Hospital, Capital Medical Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Song","sequence":"additional","affiliation":[{"name":"Medical Oncology Military General Hospital of Beijing  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangming","family":"Tian","sequence":"additional","affiliation":[{"name":"Medical Oncology Beijing Cancer Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8465-6933","authenticated-orcid":false,"given":"Yuxin","family":"Mu","sequence":"additional","affiliation":[{"name":"Medical Oncology Chinese Academy of Medical Sciences Cancer Institute and Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangchun","family":"Gu","sequence":"additional","affiliation":[{"name":"Medical Oncology Peking University Third Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[{"name":"Medical Oncology Jilin University First Hospital  Changchun China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Sun","sequence":"additional","affiliation":[{"name":"Medical Oncology Qindao University Medical College Affiliated Yantai Yuhuangding Hospital  Yantai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhong","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Peking Union Medical College Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Peking Union Medical College Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2832-2664","authenticated-orcid":false,"given":"Yan","family":"Xu","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Peking Union Medical College Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjiang","family":"Chen","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Peking Union Medical College Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhao","family":"Wang","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Peking Union Medical College Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,5,29]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"31","article-title":"Randomized phase III trial of erlotinib (E) versus docetaxel (D) as second\u2010 or third\u2010line therapy in patients with advanced non\u2010small cell lung cancer (NSCLC) who have wild\u2010type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung Cancer Trial (DELTA)","author":"Okano Y","year":"2013","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70310-3"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70385-0"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70393-X"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv276"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.2056"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70112-1"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810699"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61758-4"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70355-3"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214886"},{"key":"e_1_2_6_13_1","first-page":"1582","article-title":"First\u2010line crizotinib versus chemotherapy in ALK\u2010positive lung cancer (vol 371, pg 2167, 2014)","volume":"373","author":"Solomon BJ","year":"2015","journal-title":"New Engl J Med."},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2014.2160"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143515"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2016.17.3.965"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-015-0032-8"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000072"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000033"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2007.00607.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2511"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27553"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2010.090863"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-2969-y"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0802"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.6993"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr489"},{"key":"e_1_2_6_28_1","first-page":"14","article-title":"Gene expression and clinical characteristics of molecular targeted therapy in non\u2010small cell lung cancer patients in Shandong","volume":"20","author":"Qiao X","year":"2017","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.98979"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.13090","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1759-7714.13090","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.13090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T03:47:02Z","timestamp":1694317622000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.13090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,29]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1111\/1759-7714.13090"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.13090","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"value":"1759-7706","type":"print"},{"value":"1759-7714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,29]]},"assertion":[{"value":"2019-02-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}